Prima BioMed Long Term Debt 2010-2021 | IMMP

Prima BioMed long term debt from 2010 to 2021. Long term debt can be defined as the sum of all long term debt fields.
Prima BioMed Annual Long Term Debt
(Millions of US $)
2021 $2
2020 $6
2019 $5
2018 $5
2017 $4
2016 $4
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Prima BioMed Quarterly Long Term Debt
(Millions of US $)
2017-03-31 $4
2016-12-31 $4
2016-06-30 $4
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-06-30
2010-06-30
2009-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.185B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Emergent Biosolutions (EBS) United States $1.646B 7.05
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00